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Background. The reductions of myocardial 83-adrenergic receptor density and responsiveness to catecholamines in congestive heart failure are associated with excessive sympathetic stimulation. The purpose of this study was to determine whether the myocardial changes could be prevented by /3-receptor blockade.
Methods and Results. We administered the oral /3-receptor blocking agent nadolol (40 mg/day) to dogs during an early stage of experimental right heart failure and to sham-operated dogs for 5 weeks. Animals receiving no nadolol were studied concurrently. Nadolol treatment did not prevent right ventricular hypertrophy or elevated concentrations of plasma norepinephrine that occurred in right heart failure, nor did it affect the decrease in myocardial norepinephrine content and norepinephrine uptake activity, suggesting that the hemodynamic stress imposed on the right ventricle of dogs with right heart failure was similar regardless of the presence or absence of /3-receptor blockade. Resting heart rate, right atrial pressure, aortic pressure, cardiac output, right ventricular dP/dt, and left ventricular dP/dt and dP/dt/P measured 5 days after discontinuation of nadolol did not differ significantly from those without nadolol treatment in either right heart failure or sham-operated animals. Sham-operated dogs also showed no changes in myocardial /3-receptor or adenylate cyclase activity after nadolol treatment. However, nadolol treatment prevented the reduction of myocardial /3-receptor density and attenuated the decrease in the cardiac /3-adrenergic sensitivity that occurred in right heart failure.
Conclusions. Excessive sympathetic stimulation may play an important role in the development of /-receptor downregulation and /-adrenergic subsensitivity in right heart failure. (Circulation 1991; 84:254-266) Studies have shown that myocardial ,3-adrenergic receptor density and 8-receptor-coupled adenylate cyclase activity are reduced in the failing human ventricle.1-3 chamber-specific reduction of ,B-receptor density also has been shown to occur in the failing right ventricle (RV) produced by progressive pulmonary artery constriction and tricuspid avulsion in dogs. 4 However, the reduction of ,B-receptor-coupled adenylate cyclase system func-Liang et al Nadolol in Early Congestive Heart Failure 255 patients with dilated cardiomyopathy.8-11 More recently, Heilbrunn et al12 reported that the clinical improvements after long-term therapy with a (3-receptor blocking agent were accompanied by normalization of myocardial (3-receptor density and improved contractile responses to catecholamine stimulation with dobutamine. These findings indicate that enhanced sympathetic stimulation may contribute to progressive cardiac deterioration and that fl-receptor antagonists may be beneficial in treating patients with clinical congestive heart failure. However, little is known regarding whether early administration of fl-receptor blocking agents in patients with minimal or subclinical heart failure may prevent or retard the development of f8-receptor-coupled adenylate cyclase abnormalities.
The present study was undertaken to determine the effects of chronic fl-receptor blockade on the fl-receptor-coupled adenylate cyclase system in dogs during early RHF. We chose the nonselective, fl-receptor blocking agent nadolol13 because its long half-life allows once daily dosing; each animal received nadolol once daily for 5 weeks. Sham-operated and RHF dogs receiving no nadolol were studied as controls. Myocardial P-receptor density, adenylate cyclase activity, and norepinephrine content were measured. Contractile responses of the heart to adrenergic agonists were also studied. Furthermore, because the decrease in myocardial fl-receptor density in heart failure may be causally related to a reduction of norepinephrine neuronal reuptake,14 studies were conducted to determine whether nadolol therapy alters myocardial norepinephrine uptake activity and norepinephrine uptake-1 carrier site density.
Methods

Surgical Preparation of the Animal
Adult healthy mongrel dogs, weighing 18.4-31.6 kg, were used for the study. Animals were prepared for experimental RHF silicone rubber Jones hydraulic occluder (R.E. Jones, Silver Spring, Md.) around the main pulmonary artery. An implantable micromanometer (Konigsberg Instruments, Inc., Pasadena, Calif.) was inserted into the LV through an apical stab wound. Tygon catheters were then placed in the pulmonary artery, left atrium, and descending thoracic aorta. The catheters and the lead from the micromanometer were exteriorized at the nape of the neck. RHF was produced by progressive inflation of the pulmonary artery occluder, beginning 2 weeks after the second thoracotomy. Balloon inflation was adjusted at 4-7-day intervals for 3 weeks to produce a steady increase in right atrial pressure to 12-14 mm Hg; no further adjustments were made thereafter.
A separate group of dogs underwent two surgical procedures identical to those described above, except neither tricuspid valve avulsion nor the pulmonary artery constriction was included. Experimental Protocol RHF and sham-operated dogs were divided randomly into two experimental groups each: One group received nadolol, and the other group received no }3-receptor blocking agents. Nadolol (Princeton Pharmaceutical Products, Princeton, N.J.), 40 mg once a day, was given orally for 5 consecutive weeks beginning 2 weeks after the second thoracotomy. The dosage was determined in pilot experiments and was selected because it produced significant X3-receptor blockade. To assess the degree of fl-receptor blockade produced by nadolol in the present study, we administered serially increasing doses (10-500 ng/kg i.v.) of isoproterenol to determine the dose of isoproterenol required to raise heart rate by 25 beats/min, known as the chronotropic dose 25 (CD25),16 7 weeks after the second thoracotomy that corresponded to the end of the 5-week treatment with nadolol. CD25 was again determined 5 days after the discontinuation of nadolol therapy (8 weeks after the second thoracotomy), when resting hemodynamics, plasma catecholamine levels, and cardiac inotropic responses to isoproterenol and dobutamine were measured. Animals were killed 2 days later; the purpose of delay was to minimize acute effects of adrenergic agonists on myocardial tissue biochemical and fl-receptor determinations.
The animals were killed by a lethal injection of pentobarbital, and the hearts were excised. The RV and LV were separated and weighed. RV trabeculate muscles located in the basal portion of the free wall were dissected free for measuring isometric contraction. Tissue blocks were then removed from the RV and LV free walls 3-cm below the atrioventricular groove. A crude muscle membrane fraction was prepared immediately by homogenization and differential centrifugation14 and the pellets were stored in -70°C for measuring f-adrenergic receptors, adenylate cyclase activity, norepinephrine uptake-1 carrier density, and the sarcolemmal enzyme marker 5'-nucleotidase activity, all in duplicate or triplicate. The adrenergic responses of RV dP/dt to isoproterenol and dobutamine were markedly reduced in RHF (Figure 1 ). Split-plot design analysis of variance with repeated measures showed a highly significant p value (<0.0001) for both drug doses and the interaction of groups with drug doses, indicating that the RV dP/dt response differed significantly acropss the doses of the agonists and that the dose-dependent responses for RHF and sham-operated groups differed. The tests for the interaction of groups and nadolol treatments with doses of the agonists were not significant. However, the doseresponse curves appeared to be shifted downward after nadolol treatment in sham-operated animals, whereas they were shifted upward after nadolol treatment in RHF animals. Differences in LV dP/dt responses to isoproterenol and dobutamine among the groups were qualitatively similar to differences in RV dP/dt responses.
The maximum changes of heart rate, mean aortic pressure, RV dP/dt, LV dP/dt, and dP/dt/P produced by the largest doses of isoproterenol and dobutamine Table 3 . Isoproterenol increased heart rate and decreased mean aortic pressure. RHF control animals responded to isoproterenol with a smaller decrease in mean aortic pressure and a smaller increase in heart rate. Nadolol treatment reduced the peak increase in heart rate in shamoperated animals but did not significantly alter the peak heart rate response to isoproterenol in RHF animals. On the other hand, nadolol affected neither the heart rate nor the aortic pressure response to dobutamine. The peak adrenergic increases of RV dP/dt, LV dP/dt, and dP/dt/P were reduced in RHF animals. Although the changes were not significant, nadolol treatment decreased slightly the peak agonist-induced increases of myocardial contractile performance in sham-operated dogs and increased the peak responses in RHF dogs.
RV Weight and Myocardial and Plasma Norepinephnne Concentration
RHF was associated with an increase in RV weight, expressed either as absolute weight or as the ratio of RV to LV weights, regardless of whether the RHF animals had been treated with nadolol (Table  4 ). Nadolol treatment also had no effect on either the decrease of norepinephrine content in RV and LV or the increase in arterial plasma concentration of norepinephrine that occurred in RHF dogs.
RV Trabeculate Muscle Contraction
The cross-sectional areas of RV trabeculate muscles obtained for the studies were similar among the four groups (1.08+0.11, 1.17+0.16, 1.05+0.08, and 1.04+±0.10 mm2, respectively). Figure 2 shows and forskolin, the doses of acetylstrophanthidin were limited because acetylstrophanthidin decreased muscle tension development at higher concentrations.
Myocardial /3Adrenergic Receptor Density RHF reduced the maximum number of /-receptor sites but had no effect on the dissociation constant of the /3-receptors to [3H]dihydroalprenolol in RV (Table 5). In contrast, although RHF had no effect on LV /3-receptor density, it significantly increased the dissociation constant in LV compared with that of sham-operated controls.
Nadolol administration had no effect on myocardial ,3-receptor density or dissociation constant in shamoperated dogs. However, it prevented the reduction of RV /3-receptor density and the increase in dissociation constant in LV that occurred in RHF animals. 
Myocardial Adenylate Cyclase Activity
The responses of myocardial /3-adrenoceptor-coupled adenylate cyclase system to isoproterenol, Gpp(NH)p, and forskolin are shown in Figures 3 and 4 for RV and LV, respectively. The figures show that basal RV and LV adenylate cyclase activities were reduced in RHF controls compared with those shamoperated controls. RHF also lowered the dose-response curves of the three agonists. Furthermore, the maximum increases in cyclic AMP (Vm.) produced by isoproterenol, Gpp(NH)p, and forskolin were reduced in both ventricles of RHF dogs (Table 6) . RHF increased the concentration of isoproterenol required to produce one half of the maximal effect (Kact) in both ventricles. However, RHF did not affect the Kact for forskolin or Gpp(NH)p.
Nadolol treatment had no effect on either basal myocardial adenylate cyclase activity or responses of the /3-receptor-coupled adenylate cyclase system to isoproterenol, Gpp(NH)p, and forskolin in shamoperated dogs. However, it normalized the basal and stimulated adenylate cyclase activity in RHF dogs.
The Vma, values in RHF+nadolol were statistically indistinguishable from those in the sham-operated control and sham-operated+nadolol groups. Nadolol treatment also normalized the increase in Kact that occurred in RHF dogs (Table 6) . Manganese-Stimulated Adenylate Cyclase Activity and 5'-Nucleotidase Activity Unlike the responses to isoproterenol, Gpp-(NH)p and forskolin, the response of adenylate cyclase to manganese chloride (20 mM) was not reduced in the failing RV (Table 7) . Sham-operated control and RHF control did not differ in the 5'-nucleotidase activity of their RV or LV membrane preparation (Table 7 ). The table also shows that nadolol treatment affected neither the manganese-stimulated adenylate cyclase activity nor 5- nucleotidase activity of the myocardial membrane in the sham-operated or RHF dogs.
Myocardial Norepinephrine Uptake Activity and Uptake-i Camer Density Table 8 shows that norepinephrine uptake activity and norepinephrine uptake-1 carrier density were reduced in RV of RHF. However, neither parameter changed significantly in LV of RHF. The table further shows that the changes in RV were unaffected by nadolol treatment in either the sham-operated or RHF dogs. Norepinephrine uptake activity and norepinephrine uptake-1 carrier density were reduced to the same extent in RHF with and without nadolol treatment.
Discussion
The present study shows that early administration of nadolol prevents the development of ,B-adrenergic subsensitivity in RHF. This RHF preparation has been extensively studied by us4,14,25-28 and other investigators.29,30 The RHF dogs exhibit ascites; increased heart rate; elevated right atrial pressure; and reduced cardiac output, RV dP/dt, LV dP/dt, and dP/dt/P. Furthermore, just as reduced f3-adrenergic sensitivity occurs in patients with congestive heart failure,1-3,12 our RHF animals show a reduced chronotropic response to isoproterenol and smaller inotropic responses to isoproterenol and dobutamine. Decreases in myocardial ,3-receptor density and adenylate cyclase activity also have been shown in RHF dogs.4,14 Furthermore, our finding that the contractile response to acetylstrophanthidin was relatively preserved in RHF suggests that the subnormal inotropic response in RHF was specific to /B-adrenergic agonists, which requires a normally functional ,B-recep- tor-coupled adenylate cyclase system. Inotropic responses of ventricular trabeculae to acetylstrophanthidin also have been shown to be well preserved in the failed human myocardium.31
Nadolol treatment normalized myocardial /3-receptor number and 3-receptor-coupled adenylate cyclase activity in RHF. It also improved the responses of RV dP/dt, LV dP/dt, and dP/dt/P to isoproterenol and dobutamine in intact RHF animals and the in vitro inotropic responses of failing RV trabeculate muscles to isoproterenol and forskolin. However, the improvements in cardiac contractile function in vivo were smaller than those in trabecular muscles, possibly because a significant /3-receptor blocking effect of nadolol was still present 5 days after discontinuation of the drug when the hemodynamic studies were performed. The increase in isoproterenol CD25 and the downward shift of doseresponse curves of the in vivo myocardial contractile responses to /8-adrenergic agonists in the shamoperated+nadolol compared with the sham-operated control group are consistent with a persistent ,/-receptor inhibition. In contrast, probably little nadolol remained in the myocardium to inhibit the /3-receptor-mediated responses in the isolated muscle preparation because the in vitro studies were performed 2 days after the in vivo hemodynamic studies and because repeated washings in isolated muscle preparations could have removed unbound nadolol from the tissue.
However, nadolol had no effect on resting heart rate, mean aortic pressure, cardiac output, right and left atrial pressures, RV dP/dt, LV dP/dt, and dP/dt/P in either sham-operated or RHF animals 5 days after discontinuation of the drug. Mean arterial pressure, cardiac index, cardiac filling pressures, and LV dP/dt also were unaffected by long-term metoprolol administration in patients with dilated cardiomyopathy.12 Nevertheless, unlike our present study, human studies11,12 showed that the /-receptor blocker therapy reduced resting heart rate in patients with congestive heart failure, whereas such therapy increased LV ejection fraction and stroke work index. The difference in resting heart rate between our present study in dogs and those in humans probably was related to Our finding that 13-receptor density was reduced only in the stressed RV is consistent with our prior finding in RHF-dogs4 and with that in patients with isolated RHF secondary to pulmonary hypertension. 46 The chamber-specific reduction of /3-receptors appears to be due to increased exposure of RV to catecholamines becatse such changes were prevented by nadolol. Postreceptor abnormalities that occurred in both ventricles of the RHF dogs probably are also mediated by exposure to catecholamines because such exposure, too, is prevented by nadolol.
The mechanisms by which the different pattern of desensitization occurs in the RV and LV of RHF is uncertain. However, it is likely that RV is exposed to higher levels of interstitial norepinephrine than LV because there is a selective decrease in norepinephrine reuptake activity and norepinephrine uptake-1 carrier site density in the failing RV.14 The integrity of the norepinephrine uptake system in LV probably lessens the degree of exposure of LV to norepinephrine. Thus, we speculate that myocardial /-adrenergic responsiveness may be modulated at different levels by various concentrations of interstitial norepinephrine. Long-term exposure of the heart to moderate norepinephrine excess causes postreceptor changes, whereas /3-receptor downregulation can be produced only by more intense exposure. Further research is warranted to establish the precise mechanisms by which different patterns of desensitivity occur in the RV and LV of RHF. Our present study further shows that, unlike the responses in RHF, nadolol treatment affected neither myocardial /-receptor density nor the /3-receptor-coupled adenylate cyclase activity in sham-operated dogs. Long-term /3-receptor blockade has also been shown to exert no significant effects on myocardial /-receptors and adenylate cyclase activity in normal dogs47 and rats. 48 This is probably because the heart is not under significant sympathetic influence in normal intact animals; thus, /8-receptor inhibition would not be expected to cause "upregulation" of /3-receptors. This speculation is consistent with the observations that propranolol, which is capable of increasing /3-receptor density in the innervated embryonic chick heart, exerts no effect on the density of ,/-receptors in the noninnervated embryonic chick heart.49
Unlike /3-receptor number, norepinephrine uptake activity and norepinephrine uptake-1 carrier site density, the sarcolemmal marker 5'-nucleotidase activity did not differ in RV of sham-operated and RHF dogs. This finding, with indistinguishable myocardial adenylate cyclase responses to manganese in the two groups, indicates that the sham-operated and RHF dogs had similar sarcolemmal fractions in their crude membrane preparations and that the reductions of ,/-receptor number and norepinephrine uptake-1 carrier sites in the hypertrophied failing RV cannot be explained by dilution as the RV mass increased.
/B-Receptor density also did not change in hypertrophied RV produced by pulmonary stenosis in dogs. 50 Our study further shows that nadolol treatment neither prevented RV hypertrophy nor modified the abnormalities in norepinephrine uptake activity and norepinephrine uptake-1 site density in the failing ventricle. These findings support the concept that the reductions of /3-receptor density and norepinephrine uptake-1 carrier sites did not result from RV hypertrophy. Our results further suggest that uinlike the changes in /3-receptor density and postadenylate cyclase activity, the norepinephrine reuptake abnormalities are not mediated by norepinephrine stimulation of cardiac /3-receptors. Furthermore, because the RHF and RHF+nadolol groups did not differ in right atrial pressure, RV hypertrophy, RV norepinephrine depletion, and RV norepinephrine uptake activity, the hemodynamic stress imposed on the RV by pulmonary artery constriction probably was similar in the two RHF groups.
The abnormal sympathetic activity of the failing ventricle appears to represent an early and important event in the progression of heart failure. Excessive cardiac sympathetic stimulation may be caused by both an increase in sympathetic discharge and a decrease in norepinephrine neuronal reuptake. Although /3-receptor blockade does not affect the sympathetic neuronal functions, it does attenuate the subsequent effects on the /3-adrenergic system.
Our study provides strong support for the potential role of /3-receptor blockade in preventing the cascade of events that result in worsening heart failure. It also helps to explain the reports of improvement in symptoms and myocardial function in patients with overt heart failure.8-12 Use of /3-receptor blockers early in the course of heart failure when symptoms are mild or latent may ultimately prove to be of considerable importance in preventing subsequent severe heart failure. The present investigation was aimed at prevention; we did not study reversibility of established abnormalities. However, the work of Heilbrunn et a112 does suggest that some reversibility is possible. Additional studies are needed to fully establish the clinical efficacies and safety of long-term /3-receptor blocker therapy in patients with symptomatic and asymptomatic myocardial dysfunction. Further investigations are also required to understand the mechanisms by which abnormal norepinephrine reuptake develops and ways in which it may be prevented or reversed.
